Innate Pharma S.A.
IPHYF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -79.5% | 24.2% | 309.8% | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 100% | 9.1% | 12.1% | -184.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -371.7% | -12.3% | -24.7% | -356.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -392% | -12.3% | -117.1% | -436% |
| EPS Diluted | -0.61 | -0.09 | -0.73 | -0.57 |
| % Growth | -577.8% | 87.7% | -28.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |